KLS-101 is in lead validation; KLS-201 and KLS-301 are at the discovery stage. Candidate compounds are confidential and will be disclosed as programmes advance.
A fast-growing tumour of the brainstem that mainly affects children. Most cases are now classified as diffuse midline glioma, H3 K27-altered.
The tumour's location rules out surgery. Radiotherapy brings temporary benefit, and survival is usually measured in months.
Screening brain-penetrant approved and clinical-stage compounds against the vulnerabilities created by the H3 K27 alteration.
An inherited form of frontotemporal dementia caused by mutations in the GRN gene, which lower levels of the protein progranulin.
There is no approved disease-modifying treatment; care today focuses on managing symptoms.
Identifying existing medicines that raise progranulin or support the lysosomal function it maintains, in genetically defined carriers.
A rare cancer of cartilage-forming cells, most often arising in bone.
Advanced and metastatic disease responds poorly to conventional chemotherapy and radiotherapy, and effective systemic options are limited.
Testing repurposed compounds against the metabolic and molecular features of chondrosarcoma, with patients selected by IDH1/IDH2 status and subtype.
Pipeline information is provided for general information only. It is not medical advice and makes no claim of safety or efficacy. Compounds in development are investigational for these indications and have not been approved by any regulator for these uses.
We welcome conversations with co-development partners, clinical investigators and patient organisations.